Connection

Raymond Anton to Humans

Back to Details
This is a "connection" page, showing publications Raymond Anton has written about Humans.
Raymond Anton
Connection Strength
1.978
Humans
  1. Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone. Neuropsychopharmacology. 2022 10; 47(11):1953-1960.
    View in: PubMed
    Score: 0.032
  2. The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup. J Addict Med. 2022 Jul-Aug 01; 16(4):425-432.
    View in: PubMed
    Score: 0.031
  3. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
    View in: PubMed
    Score: 0.031
  4. Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2021 09 01; 178(9):829-837.
    View in: PubMed
    Score: 0.030
  5. Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. J Gen Intern Med. 2021 02; 36(2):404-412.
    View in: PubMed
    Score: 0.029
  6. Changed Primary Outcome Between Trial Registration and Publication-Reply. JAMA Intern Med. 2020 11 01; 180(11):1551-1552.
    View in: PubMed
    Score: 0.029
  7. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
    View in: PubMed
    Score: 0.029
  8. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2020 05 01; 180(5):728-736.
    View in: PubMed
    Score: 0.028
  9. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
    View in: PubMed
    Score: 0.028
  10. Response to Dr. Mark Litt's Commentary. Alcohol Clin Exp Res. 2019 10; 43(10):2255-2256.
    View in: PubMed
    Score: 0.027
  11. Intraindividual changes in brain GABA, glutamate, and glutamine during monitored abstinence from alcohol in treatment-naive individuals with alcohol use disorder. Addict Biol. 2020 11; 25(6):e12810.
    View in: PubMed
    Score: 0.027
  12. Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment na?ve individuals with alcohol use disorder. Neurosci Lett. 2019 07 27; 706:207-210.
    View in: PubMed
    Score: 0.026
  13. Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2019 05; 43(5):979-987.
    View in: PubMed
    Score: 0.026
  14. Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Na?ve Individuals with Alcohol Use Disorder Versus Light Drinkers. Alcohol Clin Exp Res. 2019 02; 43(2):221-226.
    View in: PubMed
    Score: 0.026
  15. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcohol Clin Exp Res. 2018 12; 42(12):2453-2465.
    View in: PubMed
    Score: 0.025
  16. Reply: Carbohydrate Deficient Transferrin in Patients with Cirrhosis: A Tale of Bridges. Alcohol Alcohol. 2018 05 01; 53(3):351-352.
    View in: PubMed
    Score: 0.024
  17. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
    View in: PubMed
    Score: 0.024
  18. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. Neuropsychopharmacology. 2018 05; 43(6):1247-1256.
    View in: PubMed
    Score: 0.024
  19. Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017 07 04; 7(7):e1163.
    View in: PubMed
    Score: 0.023
  20. Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. Alcohol Clin Exp Res. 2017 Jul; 41(7):1370-1380.
    View in: PubMed
    Score: 0.023
  21. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
    View in: PubMed
    Score: 0.023
  22. Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. Alcohol Clin Exp Res. 2017 May; 41(5):1054-1062.
    View in: PubMed
    Score: 0.023
  23. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res. 2017 01; 41(1):179-186.
    View in: PubMed
    Score: 0.022
  24. Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease. Alcohol Alcohol. 2017 Jan; 52(1):24-28.
    View in: PubMed
    Score: 0.022
  25. Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. Alcohol Alcohol. 2016 Sep; 51(5):549-54.
    View in: PubMed
    Score: 0.021
  26. The Reasons for Heavy Drinking Questionnaire: Factor Structure and Validity in Alcohol-Dependent Adults Involved in Clinical Trials. J Stud Alcohol Drugs. 2016 Mar; 77(2):354-61.
    View in: PubMed
    Score: 0.021
  27. Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence. Alcohol Clin Exp Res. 2016 Mar; 40(3):491-6.
    View in: PubMed
    Score: 0.021
  28. Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci. 2015 Jun; 17(2):181-90.
    View in: PubMed
    Score: 0.020
  29. Commentary on: ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res. 2014 Jul; 38(7):1826-8.
    View in: PubMed
    Score: 0.019
  30. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. Alcohol Alcohol. 2014 May-Jun; 49(3):261-70.
    View in: PubMed
    Score: 0.018
  31. Pharmacologic treatment of alcoholism. Handb Clin Neurol. 2014; 125:527-42.
    View in: PubMed
    Score: 0.018
  32. Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study. Addiction. 2013 Oct; 108(10):1745-6.
    View in: PubMed
    Score: 0.018
  33. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
    View in: PubMed
    Score: 0.016
  34. The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders. Neuropsychopharmacology. 2012 Jan; 37(2):402-11.
    View in: PubMed
    Score: 0.015
  35. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res. 2012 Mar; 36(3):385-94.
    View in: PubMed
    Score: 0.015
  36. Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res. 2011 Nov; 35(11):2030-8.
    View in: PubMed
    Score: 0.015
  37. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
    View in: PubMed
    Score: 0.015
  38. Liver disease and HPLC quantification of disialotransferrin for heavy alcohol use: a case series. Alcohol Clin Exp Res. 2010 Nov; 34(11):1956-60.
    View in: PubMed
    Score: 0.015
  39. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 2010 Aug; 30(4):365-72.
    View in: PubMed
    Score: 0.014
  40. Editorial commentary: alcohol biomarker papers. Alcohol Clin Exp Res. 2010 Jun; 34(6):939-40.
    View in: PubMed
    Score: 0.014
  41. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets. 2010 Mar; 9(1):50-4.
    View in: PubMed
    Score: 0.014
  42. Substance abuse is a disease of the human brain: focus on alcohol. J Law Med Ethics. 2010; 38(4):735-44.
    View in: PubMed
    Score: 0.014
  43. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug; 29(4):334-42.
    View in: PubMed
    Score: 0.013
  44. A useful test for monitoring alcohol use. Behav Healthc. 2009 Jun; 29(6):38, 40.
    View in: PubMed
    Score: 0.013
  45. COMT genotype influences the effect of alcohol on blood pressure: results from the COMBINE study. Am J Hypertens. 2009 Jan; 22(1):87-91.
    View in: PubMed
    Score: 0.013
  46. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008 Oct; 103(10):1622-8.
    View in: PubMed
    Score: 0.013
  47. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res. 2008 Nov; 32(11):1954-61.
    View in: PubMed
    Score: 0.013
  48. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008 Aug 14; 359(7):715-21.
    View in: PubMed
    Score: 0.012
  49. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008 Jun; 9(6):655-8.
    View in: PubMed
    Score: 0.012
  50. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May; 32(5):771-6.
    View in: PubMed
    Score: 0.012
  51. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008 Feb; 28(1):5-12.
    View in: PubMed
    Score: 0.012
  52. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb; 65(2):135-44.
    View in: PubMed
    Score: 0.012
  53. Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol Alcohol. 2008 Mar-Apr; 43(2):192-7.
    View in: PubMed
    Score: 0.012
  54. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603.
    View in: PubMed
    Score: 0.011
  55. Factors affecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE Study. Alcohol Clin Exp Res. 2006 Nov; 30(11):1878-83.
    View in: PubMed
    Score: 0.011
  56. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17.
    View in: PubMed
    Score: 0.011
  57. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005 Oct; 15(5):723-8.
    View in: PubMed
    Score: 0.010
  58. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
    View in: PubMed
    Score: 0.010
  59. Design and analysis of trials of combination therapies. J Stud Alcohol Suppl. 2005 Jul; (15):34-42; discussion 33.
    View in: PubMed
    Score: 0.010
  60. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl. 2005 Jul; (15):56-64; discussion 33.
    View in: PubMed
    Score: 0.010
  61. A bioactive biflavonoid from Campnosperma panamense. Fitoterapia. 2004 Dec; 75(7-8):764-7.
    View in: PubMed
    Score: 0.010
  62. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004 Nov; 28(11):1710-7.
    View in: PubMed
    Score: 0.010
  63. Recent advances in the pharmacotherapy of alcoholism. Curr Psychiatry Rep. 2004 Oct; 6(5):332-8.
    View in: PubMed
    Score: 0.010
  64. Biochemical alcohol screening in primary health care. Addict Behav. 2004 Sep; 29(7):1427-37.
    View in: PubMed
    Score: 0.009
  65. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004 Aug; 24(4):421-8.
    View in: PubMed
    Score: 0.009
  66. Self-report and biomarker alcohol screening by primary care physicians: the need to translate research into guidelines and practice. Alcohol Alcohol. 2004 Jul-Aug; 39(4):325-8.
    View in: PubMed
    Score: 0.009
  67. Following alcohol consumption, nontreatment-seeking alcoholics report greater stimulation but similar sedation compared with social drinkers. J Stud Alcohol. 2004 May; 65(3):330-5.
    View in: PubMed
    Score: 0.009
  68. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40.
    View in: PubMed
    Score: 0.009
  69. Biomarkers as aids to identification of relapse in alcoholic patients. Recent Dev Alcohol. 2003; 16:25-38.
    View in: PubMed
    Score: 0.008
  70. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict. 2003; 12(s1):s53-s68.
    View in: PubMed
    Score: 0.008
  71. A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nat Protoc. 2022 03; 17(3):567-595.
    View in: PubMed
    Score: 0.008
  72. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict. 2002; 11(2):141-50.
    View in: PubMed
    Score: 0.008
  73. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcohol Clin Exp Res. 2001 Dec; 25(12):1729-33.
    View in: PubMed
    Score: 0.008
  74. Naltrexone for alcohol dependence: comments on Morris et al. (2001). Addiction. 2001 Dec; 96(12):1855.
    View in: PubMed
    Score: 0.008
  75. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
    View in: PubMed
    Score: 0.008
  76. Saponins from Strasburgeria robusta. Fitoterapia. 2001 Jun; 72(5):591-3.
    View in: PubMed
    Score: 0.008
  77. Adolescent Obsessive-Compulsive Drinking Scale: an assessment tool for problem drinking. J Natl Med Assoc. 2001 Mar; 93(3):92-103.
    View in: PubMed
    Score: 0.007
  78. The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. Am J Psychiatry. 2021 06; 178(6):548-559.
    View in: PubMed
    Score: 0.007
  79. Clinical review of inhalants. Am J Addict. 2001; 10(1):79-94.
    View in: PubMed
    Score: 0.007
  80. Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol. 2000 Nov; 22(3):159-64.
    View in: PubMed
    Score: 0.007
  81. The Utility of Carbohydrate-Deficient Transferrin in Identifying Chronic Alcohol Users in the Injured Patient: Expanding the Toolkit. J Surg Res. 2021 01; 257:92-100.
    View in: PubMed
    Score: 0.007
  82. Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction. 2000 Aug; 95 Suppl 2:S211-7.
    View in: PubMed
    Score: 0.007
  83. Piloting of the Just Say Know prevention program: a psychoeducational approach to translating the neuroscience of addiction to youth. Am J Drug Alcohol Abuse. 2021 01 02; 47(1):16-25.
    View in: PubMed
    Score: 0.007
  84. Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. Alcohol Clin Exp Res. 2020 08; 44(8):1625-1635.
    View in: PubMed
    Score: 0.007
  85. Modulation of mistletoe (Viscum album L.) lectins cytotoxicity by carbohydrates and serum glycoproteins. Arzneimittelforschung. 2000 May; 50(5):471-8.
    View in: PubMed
    Score: 0.007
  86. Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar; 61(2):220-4.
    View in: PubMed
    Score: 0.007
  87. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
    View in: PubMed
    Score: 0.007
  88. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov; 156(11):1758-64.
    View in: PubMed
    Score: 0.007
  89. Alcohol craving--a renaissance. Alcohol Clin Exp Res. 1999 Aug; 23(8):1287-8.
    View in: PubMed
    Score: 0.007
  90. Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 08 01; 201:16-22.
    View in: PubMed
    Score: 0.007
  91. The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav. 1999 May-Jun; 24(3):449-53.
    View in: PubMed
    Score: 0.007
  92. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis. 2019 Jun; 34(6):1053-1059.
    View in: PubMed
    Score: 0.007
  93. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Psychiatry. 2019 04 01; 76(4):374-381.
    View in: PubMed
    Score: 0.007
  94. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 04 01; 197:228-235.
    View in: PubMed
    Score: 0.006
  95. Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan; 23(1):115-20.
    View in: PubMed
    Score: 0.006
  96. What is craving? Models and implications for treatment. Alcohol Res Health. 1999; 23(3):165-73.
    View in: PubMed
    Score: 0.006
  97. Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population. Alcohol Clin Exp Res. 2018 11; 42(11):2256-2265.
    View in: PubMed
    Score: 0.006
  98. The effect of drinking intensity and frequency on serum carbohydrate-deficient transferrin and gamma-glutamyl transferase levels in outpatient alcoholics. Alcohol Clin Exp Res. 1998 Oct; 22(7):1456-62.
    View in: PubMed
    Score: 0.006
  99. The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms. Addict Biol. 2019 09; 24(5):1109-1118.
    View in: PubMed
    Score: 0.006
  100. Female alcoholic outpatients and female college students: a correlational study of self-reported alcohol consumption and carbohydrate-deficient transferrin levels. J Stud Alcohol. 1998 Sep; 59(5):555-9.
    View in: PubMed
    Score: 0.006
  101. Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 07; 3(7):599-609.
    View in: PubMed
    Score: 0.006
  102. Treatment of alcohol withdrawal. Alcohol Health Res World. 1998; 22(1):38-43.
    View in: PubMed
    Score: 0.006
  103. Childhood hyperactivity, gender, and Cloninger's personality dimensions in alcoholics. Addict Behav. 1997 Sep-Oct; 22(5):649-53.
    View in: PubMed
    Score: 0.006
  104. Left frontal pole theta burst stimulation decreases orbitofrontal and insula activity in cocaine users and alcohol users. Drug Alcohol Depend. 2017 09 01; 178:310-317.
    View in: PubMed
    Score: 0.006
  105. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology (Berl). 1997 May; 131(2):123-9.
    View in: PubMed
    Score: 0.006
  106. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017 06; 4(6):469-476.
    View in: PubMed
    Score: 0.006
  107. Proposed recommendations for research on biochemical markers for problematic drinking. Alcohol Clin Exp Res. 1997 Apr; 21(2):244-7.
    View in: PubMed
    Score: 0.006
  108. Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Anticancer Drugs. 1997 Apr; 8 Suppl 1:S3-8.
    View in: PubMed
    Score: 0.006
  109. Reprint of Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT). Clin Chim Acta. 2017 Apr; 467:15-20.
    View in: PubMed
    Score: 0.006
  110. IFCC approved HPLC reference measurement procedure for the alcohol consumption biomarker carbohydrate-deficient transferrin (CDT): Its validation and use. Clin Chim Acta. 2017 Feb; 465:91-100.
    View in: PubMed
    Score: 0.006
  111. Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett. 1996 Dec 03; 109(1-2):33-8.
    View in: PubMed
    Score: 0.006
  112. The use of carbohydrate deficient transferrin as an indicator of alcohol consumption during treatment and follow-up. Alcohol Clin Exp Res. 1996 Nov; 20(8 Suppl):54A-56A.
    View in: PubMed
    Score: 0.006
  113. Pharmacotherapy of alcoholism--10 years of progress. Alcohol Clin Exp Res. 1996 Nov; 20(8 Suppl):172A-175A.
    View in: PubMed
    Score: 0.006
  114. New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res. 1996 Oct; 20(7 Suppl):3A-9A.
    View in: PubMed
    Score: 0.005
  115. The Formation, Elimination, Interpretation, and Future Research Needs of Phosphatidylethanol for Research Studies and Clinical Practice. Alcohol Clin Exp Res. 2016 11; 40(11):2292-2295.
    View in: PubMed
    Score: 0.005
  116. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res. 1996 Aug; 20(5):841-6.
    View in: PubMed
    Score: 0.005
  117. Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 2016 09; 40(9):1935-44.
    View in: PubMed
    Score: 0.005
  118. Missing Data in Alcohol Clinical Trials with Binary Outcomes. Alcohol Clin Exp Res. 2016 07; 40(7):1548-57.
    View in: PubMed
    Score: 0.005
  119. Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT). Clin Chim Acta. 2016 Aug 01; 459:19-24.
    View in: PubMed
    Score: 0.005
  120. Association between a brief alcohol craving measure and drinking in the following week. Addiction. 2016 06; 111(6):1004-10.
    View in: PubMed
    Score: 0.005
  121. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar; 53(3):225-31.
    View in: PubMed
    Score: 0.005
  122. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol. 1996 Mar; 31 Suppl 1:43-53.
    View in: PubMed
    Score: 0.005
  123. Alcohol-related seizures and the kindling effect of repeated detoxifications: the influence of cocaine. Alcohol Alcohol. 1996 Mar; 31(2):135-43.
    View in: PubMed
    Score: 0.005
  124. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol Suppl. 1996 Mar; 31(1):43-53.
    View in: PubMed
    Score: 0.005
  125. Cytotoxic activity of Amaryllidaceae alkaloids. Planta Med. 1995 Feb; 61(1):77-9.
    View in: PubMed
    Score: 0.005
  126. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb; 19(1):92-9.
    View in: PubMed
    Score: 0.005
  127. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin Neurosci. 1995; 3(3):145-54.
    View in: PubMed
    Score: 0.005
  128. Assessment issues and strategies in alcoholism treatment matching research. J Stud Alcohol Suppl. 1994 Dec; 12:92-100.
    View in: PubMed
    Score: 0.005
  129. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol. 1994 Dec; 62(6):1116-26.
    View in: PubMed
    Score: 0.005
  130. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014 Nov; 38(11):2826-34.
    View in: PubMed
    Score: 0.005
  131. Carbohydrate-deficient transferrin and gamma-glutamyltransferase as markers of heavy alcohol consumption: gender differences. Alcohol Clin Exp Res. 1994 Jun; 18(3):747-54.
    View in: PubMed
    Score: 0.005
  132. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014 Jun; 38(6):1706-11.
    View in: PubMed
    Score: 0.005
  133. Harmonization of measurement results of the alcohol biomarker carbohydrate-deficient transferrin by use of the toolbox of technical procedures of the International Consortium for Harmonization of Clinical Laboratory Results. Clin Chem. 2014 Jul; 60(7):945-53.
    View in: PubMed
    Score: 0.005
  134. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl). 2014 Sep; 231(18):3799-807.
    View in: PubMed
    Score: 0.005
  135. Risks of alcohol use disorders related to drinking patterns in the U.S. general population. J Stud Alcohol Drugs. 2014 Mar; 75(2):319-27.
    View in: PubMed
    Score: 0.005
  136. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. J Stud Alcohol Drugs. 2014 Mar; 75(2):335-46.
    View in: PubMed
    Score: 0.005
  137. Two methods for measuring carbohydrate-deficient transferrin in inpatient alcoholics and healthy controls compared. Clin Chem. 1994 Mar; 40(3):364-8.
    View in: PubMed
    Score: 0.005
  138. Genome-wide association study of alcohol dependence:significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2014 Jan; 19(1):41-9.
    View in: PubMed
    Score: 0.004
  139. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
    View in: PubMed
    Score: 0.004
  140. Response of psychotic depression subtypes to pharmacotherapy. J Affect Disord. 1993 Jun; 28(2):125-31.
    View in: PubMed
    Score: 0.004
  141. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: III. Performance of native serum and serum spiked with disialotransferrin proves that harmonization of CDT assays is possible. Clin Chem Lab Med. 2013 May; 51(5):991-6.
    View in: PubMed
    Score: 0.004
  142. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):244-50.
    View in: PubMed
    Score: 0.004
  143. Pharmacognosy of Mimosa tenuiflora (Willd.) Poiret. J Ethnopharmacol. 1993 Mar; 38(2-3):153-7.
    View in: PubMed
    Score: 0.004
  144. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
    View in: PubMed
    Score: 0.004
  145. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov; 18(6):937-46.
    View in: PubMed
    Score: 0.004
  146. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
    View in: PubMed
    Score: 0.004
  147. Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs. 1992 Oct; 3(5):507-11.
    View in: PubMed
    Score: 0.004
  148. Array-based profiling of DNA methylation changes associated with alcohol dependence. Alcohol Clin Exp Res. 2013 Jan; 37 Suppl 1:E108-15.
    View in: PubMed
    Score: 0.004
  149. Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. J Hum Genet. 2012 Oct; 57(10):670-5.
    View in: PubMed
    Score: 0.004
  150. Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol. 2012 Nov-Dec; 47(6):683-7.
    View in: PubMed
    Score: 0.004
  151. Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behav Brain Funct. 2012 May 16; 8:23.
    View in: PubMed
    Score: 0.004
  152. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. 2013 Jan; 18(1):121-33.
    View in: PubMed
    Score: 0.004
  153. Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry. 2012 Oct 15; 72(8):637-44.
    View in: PubMed
    Score: 0.004
  154. Association of COL25A1 with comorbid antisocial personality disorder and substance dependence. Biol Psychiatry. 2012 Apr 15; 71(8):733-40.
    View in: PubMed
    Score: 0.004
  155. ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One. 2011; 6(12):e28790.
    View in: PubMed
    Score: 0.004
  156. Childhood adversity increases risk for nicotine dependence and interacts with a5 nicotinic acetylcholine receptor genotype specifically in males. Neuropsychopharmacology. 2012 Feb; 37(3):669-76.
    View in: PubMed
    Score: 0.004
  157. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. Am J Med Genet B Neuropsychiatr Genet. 2011 Dec; 156B(8):960-8.
    View in: PubMed
    Score: 0.004
  158. Cytotoxic activity of Amaryllidaceae alkaloids from Crinum augustum and Crinum bulbispermum. Planta Med. 1991 Oct; 57(5):437-9.
    View in: PubMed
    Score: 0.004
  159. 5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. Psychiatr Genet. 2011 Oct; 21(5):240-8.
    View in: PubMed
    Score: 0.004
  160. GABRG1 and GABRA2 variation associated with alcohol dependence in African Americans. Alcohol Clin Exp Res. 2012 Apr; 36(4):588-93.
    View in: PubMed
    Score: 0.004
  161. No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. Mol Psychiatry. 2012 Mar; 17(3):239-41.
    View in: PubMed
    Score: 0.004
  162. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry. 2011 Sep 15; 70(6):528-36.
    View in: PubMed
    Score: 0.004
  163. Increased severity of alcohol withdrawal in in-patient alcoholics with a co-existing anxiety diagnosis. Br J Addict. 1991 Jun; 86(6):719-25.
    View in: PubMed
    Score: 0.004
  164. Association of CHRNA4 polymorphisms with smoking behavior in two populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Jun; 156B(4):421-9.
    View in: PubMed
    Score: 0.004
  165. Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage. 2011 May 01; 56(1):61-8.
    View in: PubMed
    Score: 0.004
  166. Variation in NGFB is associated with primary affective disorders in women. Am J Med Genet B Neuropsychiatr Genet. 2011 Jun; 156B(4):401-12.
    View in: PubMed
    Score: 0.004
  167. Agitated depression in substance dependence. Drug Alcohol Depend. 2011 Jul 01; 116(1-3):163-9.
    View in: PubMed
    Score: 0.004
  168. Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics. Addict Biol. 2011 Jan; 16(1):124-32.
    View in: PubMed
    Score: 0.004
  169. Perspectives on the pathophysiology of fetal alcohol syndrome. Alcohol Clin Exp Res. 1990 Dec; 14(6):807-12.
    View in: PubMed
    Score: 0.004
  170. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: II. Performance of a laboratory network running the HPLC candidate reference measurement procedure and evaluation of a candidate reference material. Clin Chem Lab Med. 2010 Nov; 48(11):1585-92.
    View in: PubMed
    Score: 0.004
  171. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990 Sep; 147(9):1203-8.
    View in: PubMed
    Score: 0.004
  172. [Flavonoids: antithrombotic agents or nutrients?]. Bull Acad Natl Med. 1990 Jun-Jul; 174(6):709-14; discussion 714-7.
    View in: PubMed
    Score: 0.004
  173. Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology. 2010 Aug; 35(9):1921-31.
    View in: PubMed
    Score: 0.004
  174. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology. 2010 Jul; 35(8):1684-92.
    View in: PubMed
    Score: 0.003
  175. Cytotoxicity on human leukemic and rat hepatoma cell lines of alkaloid extracts of Psychotria forsteriana. Planta Med. 1989 Dec; 55(6):567-8.
    View in: PubMed
    Score: 0.003
  176. Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry. 2009 Nov; 66(11):1201-9.
    View in: PubMed
    Score: 0.003
  177. Adverse childhood events as risk factors for substance dependence: partial mediation by mood and anxiety disorders. Addict Behav. 2010 Jan; 35(1):7-13.
    View in: PubMed
    Score: 0.003
  178. Subtypes of major depression in substance dependence. Addiction. 2009 Oct; 104(10):1700-9.
    View in: PubMed
    Score: 0.003
  179. CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 1989 Jul; 26(3):257-64.
    View in: PubMed
    Score: 0.003
  180. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep; 33(9):1582-8.
    View in: PubMed
    Score: 0.003
  181. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989 May; 146(5):617-21.
    View in: PubMed
    Score: 0.003
  182. Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 2009 May; 33(5):925-30.
    View in: PubMed
    Score: 0.003
  183. Population admixture modulates risk for alcohol dependence. Hum Genet. 2009 Jun; 125(5-6):605-13.
    View in: PubMed
    Score: 0.003
  184. The thyroid axis and desipramine treatment in depression. Biol Psychiatry. 1989 Mar 15; 25(6):703-9.
    View in: PubMed
    Score: 0.003
  185. Association of variants in MANEA with cocaine-related behaviors. Arch Gen Psychiatry. 2009 Mar; 66(3):267-74.
    View in: PubMed
    Score: 0.003
  186. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs. 2009 Mar; 70(2):186-96.
    View in: PubMed
    Score: 0.003
  187. Pro-opiomelanocortin gene variation related to alcohol or drug dependence: evidence and replications across family- and population-based studies. Biol Psychiatry. 2009 Jul 15; 66(2):128-36.
    View in: PubMed
    Score: 0.003
  188. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar; 33(3):383-93.
    View in: PubMed
    Score: 0.003
  189. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008 Jun 09; 168(11):1188-99.
    View in: PubMed
    Score: 0.003
  190. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008 Apr; 65(4):466-75.
    View in: PubMed
    Score: 0.003
  191. Flavonoids and traditional medicine. Prog Clin Biol Res. 1988; 280:423-39.
    View in: PubMed
    Score: 0.003
  192. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs. 2008 Jan; 69(1):5-13.
    View in: PubMed
    Score: 0.003
  193. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res. 2007 Nov; 31(11):1780-7.
    View in: PubMed
    Score: 0.003
  194. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007 Oct 10; 298(14):1641-51.
    View in: PubMed
    Score: 0.003
  195. Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene. Neuropsychopharmacology. 2008 Mar; 33(4):837-48.
    View in: PubMed
    Score: 0.003
  196. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr; 164(4 Suppl):5-123.
    View in: PubMed
    Score: 0.003
  197. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007 Feb; 31(2):221-7.
    View in: PubMed
    Score: 0.003
  198. Central nervous system prostaglandins and ethanol. Alcohol Clin Exp Res. 1987 Feb; 11(1):10-8.
    View in: PubMed
    Score: 0.003
  199. Urinary free cortisol in psychotic depression. Biol Psychiatry. 1987 Jan; 22(1):24-34.
    View in: PubMed
    Score: 0.003
  200. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. Clin Chem Lab Med. 2007; 45(4):558-62.
    View in: PubMed
    Score: 0.003
  201. The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response. J Stud Alcohol. 2006 Sep; 67(5):700-6.
    View in: PubMed
    Score: 0.003
  202. Case report of carbamazepine treatment of organic brain syndrome with psychotic features. J Clin Psychopharmacol. 1986 Aug; 6(4):232-4.
    View in: PubMed
    Score: 0.003
  203. Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry. 2006 Aug; 163(8 Suppl):5-82.
    View in: PubMed
    Score: 0.003
  204. [Traditional medicine in the Central Plateau of Haiti. 1. Study of the traditional therapeutic system in a rural socio-cultural area]. J Ethnopharmacol. 1986 Jul; 17(1):1-11.
    View in: PubMed
    Score: 0.003
  205. [Traditional medicine in the Central Plateau of Haiti. 2. Ethnopharmacologic inventory]. J Ethnopharmacol. 1986 Jul; 17(1):13-30.
    View in: PubMed
    Score: 0.003
  206. Cold pressor task reactivity: predictors of alcohol use among alcohol-dependent individuals with and without comorbid posttraumatic stress disorder. Alcohol Clin Exp Res. 2006 Jun; 30(6):938-46.
    View in: PubMed
    Score: 0.003
  207. Alcohol biomarker screening in medical and surgical settings. Alcohol Clin Exp Res. 2006 Feb; 30(2):185-93.
    View in: PubMed
    Score: 0.003
  208. Delusions of parasitosis: differential diagnosis and treatment. South Med J. 1985 Aug; 78(8):914-8.
    View in: PubMed
    Score: 0.003
  209. Revealing alcohol abuse: to ask or to test? Alcohol Clin Exp Res. 2005 Jul; 29(7):1257-63.
    View in: PubMed
    Score: 0.003
  210. Measurement and choice of drinking outcome variables in the COMBINE Study. J Stud Alcohol Suppl. 2005 Jul; (15):104-9; discussion 92-3.
    View in: PubMed
    Score: 0.003
  211. Effect of acute alcohol consumption on lithium kinetics. Clin Pharmacol Ther. 1985 Jul; 38(1):52-5.
    View in: PubMed
    Score: 0.003
  212. Excessive alcohol consumption and hypertension: clinical implications of current research. J Clin Hypertens (Greenwich). 2005 Jun; 7(6):346-51.
    View in: PubMed
    Score: 0.002
  213. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005 Mar; 29(3):395-401.
    View in: PubMed
    Score: 0.002
  214. Aspirin reduces alcohol-induced prenatal mortality and malformations in mice. Alcohol Clin Exp Res. 1984 Nov-Dec; 8(6):513-5.
    View in: PubMed
    Score: 0.002
  215. A review of genetic, biological, pharmacological, and clinical factors that affect carbohydrate-deficient transferrin levels. Alcohol Clin Exp Res. 2004 Sep; 28(9):1347-55.
    View in: PubMed
    Score: 0.002
  216. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004 Sep; 28(9):1362-70.
    View in: PubMed
    Score: 0.002
  217. Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol Alcohol. 2004 Jul-Aug; 39(4):271-5.
    View in: PubMed
    Score: 0.002
  218. Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? Compr Psychiatry. 2004 Jul-Aug; 45(4):304-10.
    View in: PubMed
    Score: 0.002
  219. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. 2004 Feb; 29(2):393-402.
    View in: PubMed
    Score: 0.002
  220. Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem Toxicol. 2003 Dec; 41(12):1625-49.
    View in: PubMed
    Score: 0.002
  221. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003 Dec; 23(6):553-62.
    View in: PubMed
    Score: 0.002
  222. Amoxapine elevates serum prolactin in depressed men. J Affect Disord. 1983 Nov; 5(4):305-10.
    View in: PubMed
    Score: 0.002
  223. Efficacy of amoxapine in psychotic depression. Am J Psychiatry. 1983 Oct; 140(10):1344-7.
    View in: PubMed
    Score: 0.002
  224. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res. 2003 Sep; 27(9):1402-8.
    View in: PubMed
    Score: 0.002
  225. Pimozide in delusions of parasitosis. J Clin Psychiatry. 1983 Jun; 44(6):233.
    View in: PubMed
    Score: 0.002
  226. Effect of prenatal alcohol exposure on consumption of alcohol and alcohol-induced sleep time in mice. Pharmacol Biochem Behav. 1983; 18 Suppl 1:325-9.
    View in: PubMed
    Score: 0.002
  227. New constructs and assessments for relapse and continued use potential in the ASAM Patient Placement Criteria. J Addict Dis. 2003; 22 Suppl 1:95-111.
    View in: PubMed
    Score: 0.002
  228. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003 Apr; 28(4):755-64.
    View in: PubMed
    Score: 0.002
  229. Plants of Haiti used as antifertility agents. J Ethnopharmacol. 1982 Jul; 6(1):67-84.
    View in: PubMed
    Score: 0.002
  230. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend. 1981 Sep; 8(2):157-68.
    View in: PubMed
    Score: 0.002
  231. Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues. Arch Gen Psychiatry. 2001 Apr; 58(4):345-52.
    View in: PubMed
    Score: 0.002
  232. The role of craving in alcohol use, dependence, and treatment. Alcohol Clin Exp Res. 2001 Feb; 25(2):299-308.
    View in: PubMed
    Score: 0.002
  233. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov-Dec; 35(6):587-93.
    View in: PubMed
    Score: 0.002
  234. Linoleic acid in the treatment of lithium toxicity and familial tremor. Prostaglandins Med. 1980 Oct; 5(4):321-2.
    View in: PubMed
    Score: 0.002
  235. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000 Aug 01; 60(2):161-8.
    View in: PubMed
    Score: 0.002
  236. Recurrent detoxification may elevate alcohol craving as measured by the Obsessive Compulsive Drinking scale. Alcohol. 2000 Feb; 20(2):181-5.
    View in: PubMed
    Score: 0.002
  237. Talk is cheap: measuring drinking outcomes in clinical trials. J Stud Alcohol. 2000 Jan; 61(1):55-63.
    View in: PubMed
    Score: 0.002
  238. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999 Sep; 23(9):1484-91.
    View in: PubMed
    Score: 0.002
  239. Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
    View in: PubMed
    Score: 0.002
  240. Carbohydrate-deficient transferrin and alcohol use in medical examiner cases. Alcohol. 1999 Jan; 17(1):7-11.
    View in: PubMed
    Score: 0.002
  241. Further validation of the Obsessive-Compulsive Drinking Scale (OCDS). Relationship to alcoholism severity. Am J Addict. 1998; 7(1):14-23.
    View in: PubMed
    Score: 0.001
  242. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl). 1996 Nov; 128(2):206-15.
    View in: PubMed
    Score: 0.001
  243. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology. 1996 Sep; 15(3):288-95.
    View in: PubMed
    Score: 0.001
  244. Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem. 1995 Jun; 41(6 Pt 1):858-61.
    View in: PubMed
    Score: 0.001
  245. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
    View in: PubMed
    Score: 0.001
  246. Carbohydrate-deficient transferrin levels in a female population. Alcohol Clin Exp Res. 1995 Feb; 19(1):100-3.
    View in: PubMed
    Score: 0.001
  247. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol Suppl. 1994 Dec; 12:101-11.
    View in: PubMed
    Score: 0.001
  248. Multisite clinical trials in alcoholism treatment research: organizational, methodological and management issues. J Stud Alcohol Suppl. 1994 Dec; 12:30-7.
    View in: PubMed
    Score: 0.001
  249. Carbohydrate-deficient transferrin as a measure of immoderate drinking: remaining issues. Alcohol Clin Exp Res. 1994 Aug; 18(4):799-812.
    View in: PubMed
    Score: 0.001
  250. Mood congruent and incongruent psychotic depressions: are they the same? J Affect Disord. 1994 Aug; 31(4):275-80.
    View in: PubMed
    Score: 0.001
  251. A correlational study of carbohydrate-deficient transferrin values and alcohol consumption among Hispanic college students. Alcohol Clin Exp Res. 1994 Jun; 18(3):653-6.
    View in: PubMed
    Score: 0.001
  252. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry. 1993 Jul; 150(7):1125-6.
    View in: PubMed
    Score: 0.001
  253. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992 Dec; 16(6):1007-13.
    View in: PubMed
    Score: 0.001
  254. Cocaine abuse among schizophrenic patients. Am J Psychiatry. 1990 Sep; 147(9):1164-7.
    View in: PubMed
    Score: 0.001
  255. Thyrotropin and prolactin response to thyrotropin-releasing hormone in depressed and nondepressed alcoholic men. Biol Psychiatry. 1990 Jan 01; 27(1):31-8.
    View in: PubMed
    Score: 0.001
  256. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989 Sep 22-29; 262(12):1646-52.
    View in: PubMed
    Score: 0.001
  257. Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry. 1989 Apr 01; 25(7):873-8.
    View in: PubMed
    Score: 0.001
  258. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
    View in: PubMed
    Score: 0.001
  259. Alcohol, pregnancy, and prostaglandins. Alcohol Clin Exp Res. 1987 Feb; 11(1):32-6.
    View in: PubMed
    Score: 0.001
  260. Adrenalectomy reduces alcohol-stimulated activity: blood and brain alcohol content. Pharmacol Biochem Behav. 1984 Jun; 20(6):883-6.
    View in: PubMed
    Score: 0.001
  261. Noninvasive measurement of cardiac ejection fraction during desipramine treatment. Psychosomatics. 1982 Jul; 23(7):759-61.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.